INTRODUCTION

Fibromyalgia syndrome (FMS) is a condition characterized by high levels of pain, sleep disturbances and fatigue combined with a general increase in memory disturbances leading to psychological distress. The FMS frequently affects the quality of life.

The chronic non-malignant pain has been reported to affect 19-24% of the general population, and quality of life of their relatives especially female relatives is impaired. The prevalence of fibromyalgia in general population estimated to be 5.4% in a meta-analysis published from UK.

Fibromyalgia used to be defined by American College of Rheumatology as Widespread Pain for at least three months and presence of at least 11 of 18 tender points on examination. In 2010, a new-criteria was proposed that focused more on multiple symptoms and was further modified to require only self-report of symptoms.
Chronic Kidney Disease (CKD) is an important health problem worldwide causing heavy burden on patients and their families with an estimated overall prevalence of 8-16%. A number of common complaints are similar to FMS symptoms in CKD patients such as pain, chronic fatigue, sleep disturbances, psychiatric co-morbidities such as depression and anxiety and restless leg syndrome. Therefore, it is important to rule out other disorders from FMS and provide appropriate treatment to such patients.

There is limited literature available for FMS prevalence in pre-dialysis CKD patients and none published from Pakistan. Fibromyalgia is a difficult disorder to diagnose and this study is designed to assess the frequency of fibromyalgia in patients with chronic kidney disease (Stage-III and IV) so that by diagnosing and appropriately treating Fibromyalgia, we can improve patient quality of life and spread awareness among the physicians regarding this underdiagnosed and untreated condition.

**METHODS**

This cross-sectional study was carried out at outpatient department of Sindh Institute of Urology and Transplantation, Karachi, Pakistan. Study period was six months starting from January to July 2020. Sample size was calculated from reported frequency of 18.4% in pre-dialysis CKD patients, with margin of error 6% at 95% confidence level there were 154 patients were required. Inclusion criteria was all adults from both gender CKD stage-III and IV patients. While exclusion criteria were patients on dialysis or having other co-morbidities which can cause fatigue for example anemia, hypothyroidism, hepatitis, vitamin D deficiency, secondary hyperparathyroidism and hyperuricemia.

CKD staging was done according to KDIGO guidelines. Symptom Widespread Pain Index (WPI) enlists 19 areas of the body where fibromyalgia patients have pain. WPI was recorded by taking history and examining these sites. WPI score can be between 0-19. Severity Scale (SS) was recorded according to American College of Rheumatology (ACR) criteria for fibromyalgia. The maximum score on SS is 12. A person was labelled to have fibromyalgia if criteria one or two are met. Whereas, as criteria one is WPI of ≥ 7 with SS of ≥ 5 and criteria two is WPI 3-6 and SS ≥ 9. SS 2a which address fatigue, waking unrefreshed and cognitive symptoms, while 2b addresses other systematic symptoms experienced by patient during previous week when they were interviewed. This is in accordance with defined criteria by ACR.

After getting approval from institutional research and ethics review committee and informed consent from patients the data was recorded. All patients were interviewed in their native language and information was collected about the site of the pain during previous week and their WPI score was calculated accordingly. SS was assessed as per the symptoms mentioned in the Criteria (SS 2a and 2b). An annexure describing the scoring system is provided with this manuscript.

In all patients Complete Blood Picture (CBC), inflammatory markers like ESR and CRP, viral Serology for hepatitis B and C, Bone Chemistry (that includes Serum Calcium, Phosphorous, Alkaline Phosphatase and Albumin) and Uric Acid values was recorded.

**Statistical analysis:** All the data was entered and analyzed in SPSS version 22. Mean and standard deviation was determined for continuous variables such as age and duration of symptoms. Categorical variables like gender, stages of CKD (III or IV), WPI score, SS 2a, SS 2b and fibromyalgia present or absent was determined and presented as frequencies and percentages. Effect modifier such as age and gender were stratified and association was assessed with fibromyalgia in CKD Stage III and IV by using parametric student t test and non-parametric Mann Whitney U test (as skewed distribution was seen in data) and normality test using Kolmogorov-Smirnov test. P-value of < 0.05 was considered as significant.

**RESULTS**

During the study period of six months 161 patients with stage III and IV were registered in outpatient, mean age of these patients was

| Parameters          | Mean ±STD | Median | Range |
|---------------------|-----------|--------|-------|
| Age (years)         | 47.12±9.27| 48     | 21-60 |
| Hemoglobin (g/dl)   | 11.10±1.54| 11     | 9-15  |
| Albumin (mg/dl)     | 2.9±0.74  | 3      | 1.6-5.2|
| Calcium (mg/dl)     | 8.5±1.87  | 8.3    | 6-11  |
| Phosphorus (mg/dl)  | 3.14±0.78 | 3.1    | 1.6-6  |
| Alkaline phosphatase (U/L) | 70.22±36.77 | 63.5 | 31-224 |
| Uric acid (mg/dl)   | 3.87±1.42 | 3.7    | 1.5-7.4|
47.12±9.27 (range 21-60) years. There were 81 male and 80 female patients. Hepatitis B and C status and other inflammatory markers were negative in all studied population. Other demographic and laboratory parameters are given in Table-I. There were 22 (13.66%) patients found to have FMS. Mean WPI score was 5.68±4.36 (range 1-16), while SS 2a was 3.17±1.78 (range 1-9) and SS2b 2.04±0.96 (range 1-5) was recorded. Vitamin D levels are not available for all patients, therefore not described in table. Different causes of CKD in both groups are described in Table-III.

**DISCUSSION**

The diagnosis of FMS is notably clinical and is made by assessing the patients with history and clinical examination according to established criteria. In addition to diffuse pain in skeletal muscle and the physical examination finding of multiple tender points, most patients with FMS also report fatigue, muscle stiffness, pain after exertion, and sleep disturbances. The findings of the current study have reported frequency of FMS observed in 13.66% in patients with CKD stages III and IV. A study published from Turkey has reported a little higher prevalence of 18.4% in pre dialysis and 25.7% in dialysis CKD patients. A survey done in five European countries in general population has revealed the 14% prevalence of fibromyalgia. Whereas a National Health survey done in US has reported a prevalence of about 2% in general population. Another study from Turkey reveals higher prevalence in hemodialysis patients and statistically significant differences in cognitive symptoms between fibromyalgia and non-fibromyalgia groups. In yet another study published from Brazil, the prevalence was reported as 3.9% in dialysis population which was interestingly similar to general population. They observed female predominance in this study. In present study we found male to female ratio in FMS group as 1.2:1, males were slightly higher in number than female in our population.

According to an Iranian study 12.2% of 148 hemodialysis patients were suffering from fibromyalgia with higher depression and anxiety levels found in these patients. After doing search using different search engines; for any study published from our country, Pakistan; looking at fibromyalgia in chronic kidney disease patients we found no study on this particular subject, though one in patients with rheumatoid arthritis was done at a hospital in Karachi.

According to the current study findings, no significant association of FMS was found with CKD stages when fibromyalgia group compared with no fibromyalgia (p value 0.159) (Table-II) The high prevalence of chronic pain in CKD population affects quality of life in adverse fashion. A published meta-analysis which includes 36 studies examining over 5,200 patients (mostly patients on dialysis) reports that over 58% of CKD patients experience chronic pain and 49% of these rates this pain as moderate or severe.

In the current study, a higher frequency of FMS was noted in patients with more than 45 years of age. Somewhat similar findings were reported in

| Table-II: Parameters statistical comparison among two groups. (n=161). |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Parameter                  | Fibromyalgia (n=22)         | No Fibromyalgia (n=139)     | P-value                    |
| Age                        |                             |                             |                            |
| < 45 year                  | 8                           | 36                          | 0.109                      |
| >45 years                  | 14                          | 103                         |                            |
| Gender                     |                             |                             |                            |
| Male                       | 12                          | 68                          | 0.81                       |
| Female                     | 10                          | 71                          |                            |
| CKD stages                 |                             |                             |                            |
| III                        | 8                           | 73                          | 0.159                      |
| IV                         | 14                          | 66                          |                            |
| WPI score                  | 11.82 ± 1.94                | 4.44 ± 3.13                 | <0.001                     |
| SS score 2a                | 5.05 ±1.36                  | 2.71 ± 1.45                 | <0.001                     |
| SS score 2b                | 2.45 ±0.73                  | 1.79 ± 0.68                 | <0.001                     |

| Table-III: Causes of CKD in studied population (n=161). |
|--------------------------------------------------------|
| Causes                                                  |
|                                                        |
| Fibromyalgia (n=22)                                     | No Fibromyalgia (n=139) |
| Renal Calculous Disease                                 | 3 | 25 |
| Systemic Lupus                                         | 1 | 9  |
| Erythematosis                                           | 1 | 9  |
| Renal Artery Stenosis                                   | 0 | 1  |
| Hypertension                                            | 8 | 22 |
| Glomerulonephritis                                     | 3 | 19 |
| Diabetes and Hypertension                               | 3 | 16 |
| Diabetes Mellitus                                      | 0 | 4  |
| Adult Polycystic Kidney                                 | 1 | 12 |
| Disease                                                | 1 | 12 |
| Acute Cortical Necrosis                                 | 0 | 11 |
| Unknown                                                 | 3 | 20 |
Our study is first to report FMS in CKD stages III and IV from Pakistan. The frequency of fibromyalgia was found to be 13.66% in patients with CKD stage III-IV. Detection and treatment of fibromyalgia may lead to improvement in the quality of life of CKD patients. Therefore, we suggest the evaluation of the symptoms of FMS in patients with CKD.

Acknowledgement: Valuable help of Mr. Iqbal Mujtaba (Research Dept. SIUT) for statistical analysis of data is gratefully acknowledged.

Conflict of interest: None.

Funding: None.

REFERENCES
1. Samimaghah H, Haghighi A, Tayebi M, Jenabi A, Arabi M, Kianmehr N. Prevalence of fibromyalgia in hemodialysis patients. Iran J Kidney Dis. 2014;8(3):236-239.
2. Eriksen J, Jensen MK, Sjogren P, Ekholm O, Rasmussen NK. Epidemiology of chronic non-malignant pain in Denmark. Pain. 2005;105(3):221-228. doi: 10.1016/S0304-3959(03)00225-2
3. Rustoen T, Wahl AK, Hanestad BR, Lerdal A, Paul S, Mikkowski C. Prevalence and characteristics of chronic pain in the general Norwegian population. Eur J Pain. 2004;8(6):555-565. doi: 10.1016/j.ejpain.2004.02.002
4. Neumann L, Buskila D. Quality of life and physical functioning of relatives of fibromyalgia patients. Semin Arthritis Rheum. 1997;26(6):834-839. doi: 10.1016/S0049-0172(97)80027-3
5. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: A systematic review and meta-analysis of population studies. BMJ Open. 2016;6(6):e013064. doi:10.1136/bmjopen-2015-013064
6. Wolfe F, Smyte HA, Yunus MB, Bennett RB, Bombardier C. The American College of Rheumatology 1990 Criteria for Classification of Fibromyalgia: Report of the Multicentre Criteria Committee. Arthritis Rheum. 1990;33(2):160-172. doi: 10.1002/art.1780330203
7. Jones GT, Atzeni F, Beasley M, Flub E, Puttini PS, Macfarlane GJ. The prevalence of fibromyalgia in the general population: A comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 2015;67(2):568-575. doi: 10.1002/art.38905
8. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease. Global dimension & perspectives. Lancet. 2013;382(9888):260-272. doi: 10.1016/S0140-6736(13)60687-X
9. Prelicjevic VT, Osthubs TB, Sandvik L, Bringager CB, Opdirdsmeo S, Nordhus IH, et al. Psychiatric disorders, body mass index and C-reactive protein in dialysis patients. Gen Hosp Psychiatry. 2011;33(5):454-461. doi: 10.1016/j.genhosppsych.2011.06.010
10. Koca T, Yigit I. Fibromyalgia prevalence and its association with laboratory parameters in patients with chronic renal failure: A Single-Centered Study from Turkey. Acta Medica. 2017;48(4):12-17.
11. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kid Int. 2005;67:2089-2100. doi: 10.1111/j.1523-1755.2005.00365.x
12. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, et al. Prevalence of fibromyalgia: A survey in five European countries. Semin Arthritis Rheum. 2010;39:448-453. doi: 10.1016/j.semarthrit.2008.12.003
13. Walitt B, Nahn RL, Katz RS, Bergman MJ, Wolfe F. The prevalence and characteristics of fibromyalgia in the 2012 National Health Interview Survey. PLoS One. 2015;10(9):e0138024. doi:10.1371/journal.pone.0138024
14. Lelebici C, Ozelsancak R, Yilmaz EF, Doruk F. Fibromyalgia syndrome in Turkish hemodialysis patients. Hemodial Int. 2016;20:106-110. doi: 10.1011/hdi.20132
15. Couto CI, Natour J, Carvalho AB. Fibromyalgia: Its prevalence and impact on the quality of life on a hemodialyzed population. Hemodial Int. 2008;12(1):66-72. doi: 10.1111/j.1542-4758.2008.00243.x
16. Abbasi L, Haidri FR. Fibromyalgia Complicating Disease Management in Rheumatoid Arthritis. J Coll of Phys Surg. 2014;24(6):424-427
17. Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dial. 2014;27:188-204. doi: 10.1111/semi.12196
18. Campos RP, Vazquez MI. The impact of Fibromyalgia on health-related quality of life in patients according to age. Rheumatol Int. 2013;33(6):1419-1424. doi: 10.1007/s00296-012-2568-0